PT-10 (10mg)

PT-10 (10mg): Thymus Gland Bioregulator Peptide — a Khavinson Short-Peptide Immunomodulator Originating from 1970s Soviet Military Thymus Extract Research, Later Standardized as Defined Synthetic Short Peptides (Including the Glu-Trp [EW] Dipeptide Known as Thymogen/Thymagen, the Lys-Glu [KE] Dipeptide Known as Vilon, and the Glu-Asp-Pro [EDP] Tripeptide), Which Are Proposed to Enter Thymic Epithelial Cells and Lymphocytes, Bind Complementarily to Specific DNA Sequences and Histone Proteins, Modulate Gene Expression of Heat-Shock Proteins and Cytokines, Promote T-Cell Precursor Maturation Through the CD4-CD8- Double-Negative → CD4+CD8+ Double-Positive → Mature CD4+ Helper or CD8+ Cytotoxic T-Cell Pathway, Reverse Age-Related Thymic Involution (Increasing Thymic Output as Measured by TREC Counts and Naive T-Cell Ratios), Normalize Immune Cell Ratios (CD4/CD8), Activate Natural Killer Cells, Reduce Apoptosis of Lymphoid Cells, and Restore Immune Homeostasis — With Extensive Russian Clinical Data (Including a 25-Year Study of 800 Patients Showing 28% Reduced Mortality and 40% Reduced Infectious Disease, a 6-Year Cohort of 266 Elderly Subjects Showing ~2-Fold Reduced All-Cause Mortality, and Combined Use with Epithalon Showing 4.1-Fold Mortality Reduction) but No FDA Approval and Limited Western Peer-Reviewed Replication

PT-10 is a thymus gland bioregulator peptide belonging to the Khavinson family of short peptide bioregulators (also called cytomedines or cytogens) — a class of very short peptides (typically 2-4 amino acids) developed by Professor Vladimir Khavinson and his research group, originally at the Military Medical Academy in Leningrad (now Saint Petersburg) and later at the Saint Petersburg Institute of Bioregulation and Gerontology, based on the pioneering hypothesis that each organ and tissue produces specific short peptide regulators that maintain normal function, that production of these tissue-specific peptides declines with aging, and that exogenous administration of the synthetic peptide can restore age-related functional decline in the target tissue by modulating gene expression at the epigenetic level. PT-10 is the thymus-tissue-specific member of this family, designed to interact preferentially with thymic epithelial cells (the specialized epithelial cells that form the thymic microenvironment and produce thymic hormones and cytokines essential for T-cell development) and with developing T lymphocytes (thymocytes) at various stages of maturation — supporting thymic function, promoting T-cell maturation, reversing age-related thymic involution, normalizing immune cell ratios, and restoring immune homeostasis. The history of PT-10 and thymic peptide bioregulation is deeply intertwined with the broader history of the Khavinson program and Soviet military medical research: in the 1970s, Khavinson and his colleague Vyacheslav Morozov, working at the Military Medical Academy in Leningrad, began extracting and characterizing peptide complexes from various animal tissues, starting with the thymus gland — based on the observation that thymic function declines dramatically with age (a process called thymic involution, which begins as early as the first year of life and accelerates after puberty, leading to progressive replacement of thymic tissue with fat and fibrous connective tissue, and a corresponding decline in the production of new, naive T cells — a key driver of immunosenescence, the age-related decline in immune function that makes older individuals more susceptible to infections, cancer, and autoimmune disease). The original thymic peptide complex, extracted from the thymus glands of young calves, was named Thymalin — a polypeptide complex containing a mixture of short peptides (ranging from 2 to 8 amino acids in length), which was approved for medical application as an immunomodulator by USSR Ministry of Health Order No. 1008 of November 10, 1982 (Registration No. 82.1008.8), making it one of the first peptide bioregulators to receive regulatory approval, and it remains in clinical use in Russia today (manufactured by Samson-Med). Subsequent research by Khavinson's group used reverse-phase high-performance liquid chromatography (HPLC) to isolate and identify the specific short peptide components responsible for Thymalin's biological activity, leading to the identification and chemical synthesis of several defined short peptides: the Glu-Trp (EW) dipeptide, known as Thymogen (also called Thymagen in some references), which is considered one of the primary active components of Thymalin; the Lys-Glu (KE) dipeptide, known as Vilon, another Khavinson short peptide with immunomodulatory and vascular effects; and the Glu-Asp-Pro (EDP) tripeptide, another active component of the Thymalin complex. These defined synthetic short peptides — particularly the EW dipeptide (Thymogen) — are the chemically defined, single-compound counterparts to the older natural-extract Thymalin preparation, offering the advantages of reproducible composition, no batch-to-batch variability, and no risk of animal-derived contaminants or pathogens, while retaining the proposed biological activity of the natural extract. PT-10, as a thymus-targeted peptide bioregulator product, is based on this body of research and contains defined synthetic thymic short peptides (consistent with the EW/KE/EDP active principles identified in Thymalin), manufactured to high purity standards for research use. As very short peptides (2-3 amino acids, molecular weights of approximately 250-400 Daltons), these thymic peptides are small enough to be rapidly distributed systemically after administration and to penetrate cell membranes, entering the cytoplasm and then the nucleus of target cells, where they can interact with nuclear and chromatin structures — properties that underlie their proposed mechanism of action as epigenetic regulators of gene expression, rather than as conventional receptor-mediated signaling molecules^{[1][2][3][4][5][6]}.

Mechanism of Action: DNA/Histone Binding, Gene Expression Modulation, T-Cell Maturation, and Thymic Involution Reversal

The proposed mechanism of action of PT-10 and its constituent thymic short peptides (EW, KE, EDP) — like other Khavinson peptide bioregulators — is fundamentally epigenetic and gene-regulatory, rather than receptor-mediated or enzymatic. Unlike most conventional drugs, peptide hormones, and cytokines that act by binding to specific cell-surface receptors (G protein-coupled receptors, receptor tyrosine kinases, cytokine receptors, etc.) and triggering intracellular signaling cascades, the Khavinson short peptides are proposed to act directly at the level of chromatin structure and gene expression — entering the cell nucleus, binding complementarily to specific DNA sequences in gene promoter regions and to histone proteins, and modifying the epigenetic landscape to restore more youthful patterns of gene expression in thymic cells and lymphocytes. This mechanism is supported by molecular studies demonstrating that the short peptides EW (Thymogen), KE (Vilon), and EDP — the active components of Thymalin — are able to complementarily bind to certain DNA sequences or histone proteins, and that as a result of this binding, there is a change in gene expression and the synthesis of heat-shock proteins, cytokines, and other immunoregulatory molecules. The proposed mechanism involves the following key steps and effects^{[1][2][3][7][8]}:

Step 1 — Systemic distribution and thymic tissue targeting: After administration (typically by subcutaneous or intramuscular injection), PT-10's constituent short peptides (EW, KE, EDP) — being very small molecules (2-3 amino acids, molecular weights of approximately 250-400 Daltons) — are rapidly absorbed and distributed systemically. The tissue specificity for the thymus is proposed to arise from the specific amino acid sequences of these peptides, which determine preferential binding to DNA regulatory elements (promoter regions) of thymus-specific and immune-related genes — rather than from receptor-mediated tissue targeting (as seen with antibody-drug conjugates or receptor-targeted therapies). In other words, while the peptides may distribute to many tissues, their biological effects are proposed to be most pronounced in thymic cells and lymphocytes because the EW/KE/EDP sequences preferentially recognize and bind to DNA sequences that are particularly relevant to thymic and immune gene expression, and because these cells have a particular epigenetic state (with age-silenced immune-related genes packaged in heterochromatin) that is responsive to the peptides' chromatin-modulating activity. This proposed mechanism of sequence-specific DNA binding as the basis for tissue specificity is a central tenet of the Khavinson theory but remains a working hypothesis that has not been fully confirmed by high-resolution structural studies (such as X-ray crystallography of peptide-DNA complexes or ChIP-seq to demonstrate genome-wide binding patterns) in mainstream molecular biology^[1][2][3][7].

Step 2 — Cellular uptake and nuclear entry: Once the thymic peptides reach the thymus and immune tissues, they are proposed to penetrate the cell membranes of thymic epithelial cells and developing lymphocytes (thymocytes) — a property facilitated by their small size (2-3 amino acids) and by the presence of charged amino acids (glutamic acid, aspartic acid, lysine) that may facilitate interaction with cell membranes and promote uptake. After entering the cytoplasm, the peptides are proposed to translocate to the nucleus — possibly through passive diffusion through nuclear pore complexes (which allow passage of molecules smaller than ~40-60 kDa, so a 250-400 Da peptide easily passes) or through active nuclear import mechanisms. Once inside the nucleus, the peptides can interact with nuclear and chromatin structures — specifically, with DNA (particularly the promoter regions of thymus-specific and immune-related genes) and with histone proteins (the core proteins around which DNA is wrapped to form nucleosomes, the basic units of chromatin)^[1][2][3][7].

Step 3 — Complementary DNA and histone binding — chromatin remodeling and gene expression modulation: The central mechanistic step is the proposed complementary binding of the short peptides (EW, KE, EDP) to specific DNA sequences in gene promoter regions and to histone proteins, leading to chromatin remodeling and changes in gene expression. Molecular studies by Khavinson's group have demonstrated that these peptides are able to complementarily bind to certain DNA sequences or histone proteins, and that as a result of this binding, there is a change in gene expression — including the synthesis of heat-shock proteins (which play critical roles in protein folding, cellular stress responses, and immune regulation), cytokines (signaling molecules that coordinate immune responses), and other immunoregulatory molecules. The proposed mechanism involves: (a) binding to specific DNA sequences in the promoter regions of thymus-specific and immune-related genes (particularly genes that have become silenced with age or during immunodeficiency states); (b) binding to histone proteins and modifying their post-translational modification state (such as increasing histone acetylation — associated with euchromatin and transcriptional activation — or reducing histone methylation marks associated with heterochromatin, such as H3K9me3 or H3K27me3); (c) thereby decondensing heterochromatin — converting the tightly packed, transcriptionally silent DNA back into open, accessible, transcriptionally active euchromatin; and (d) restoring transcriptional access to age-silenced genes, allowing them to be re-expressed and thereby restoring more youthful patterns of gene expression in thymic cells and lymphocytes. This chromatin-decondensing and gene-reactivating mechanism is consistent with the broader Khavinson theory of peptide bioregulation, and with the observed effects of these peptides on immune function and thymic involution^{[1][2][3][7][8]}.

Step 4 — Downstream biological effects: T-cell maturation, thymic involution reversal, immune homeostasis restoration: As a consequence of chromatin remodeling and gene expression modulation, PT-10 produces a cascade of downstream biological effects that collectively restore immune function and reverse age-related immune decline (immunosenescence). These effects include: (a) promotion of T-cell precursor maturation — the peptides promote the differentiation and maturation of T-lymphocyte precursors (thymocytes) through the normal developmental pathway in the thymus: from CD4-CD8- double-negative (DN) precursors, through the CD4+CD8+ double-positive (DP) stage (where thymic selection — positive selection for self-MHC restriction and negative selection for self-tolerance — occurs), into mature CD4+ helper T cells or CD8+ cytotoxic T cells that exit the thymus as functional naive T cells; this is supported by studies showing that Thymalin normalizes differentiation and proliferation and reduces apoptosis of lymphoid cells, and activates cellular immunity reactions and regeneration processes; (b) reversal of age-related thymic involution — published rodent and human-subject research reports improvement in age-related thymic-involution markers, including increased thymic output as measured by T-cell receptor excision circle (TREC) counts (a molecular marker of recent thymic emigrants) and improved naive T-cell ratios (CD45RA+ T cells, which are newly produced, antigen-inexperienced T cells that decline with age); this is particularly significant because thymic involution — the progressive replacement of functional thymic tissue with fat and fibrous connective tissue, beginning in early life and accelerating after puberty — is considered the primary driver of immunosenescence, and reversing it has been a major goal of aging research; (c) normalization of immune cell ratios — the peptides normalize the CD4/CD8 T-cell ratio (a key indicator of immune health, which becomes dysregulated with aging and in various immunodeficiency states), with studies showing restoration of the balance of key immune-cell types; (d) activation of natural killer (NK) cells — Thymalin is reported to "wake up" natural-killer cells, which are critical components of the innate immune system responsible for killing virally infected cells and tumor cells; (e) cytokine modulation — the peptides modulate the production and balance of cytokines (immune signaling molecules), including pro-inflammatory and anti-inflammatory cytokines, helping to restore immune homeostasis rather than simply suppressing or stimulating immunity indiscriminately; (f) reduction of lymphocyte apoptosis — Thymalin reduces apoptosis (programmed cell death) of lymphoid cells, helping to preserve immune cell populations; and (g) heat-shock protein regulation — the peptides regulate the synthesis of heat-shock proteins, which play important roles in protein folding, cellular stress responses, antigen presentation, and immune regulation. Importantly, PT-10 and Thymalin act as immunomodulators (regulators of immune balance) rather than as conventional immunostimulants (which simply boost immune activity indiscriminately) — they don't just "boost" immunity, but rather restore the balance of immune responses, normalizing both underactive and overactive immune states, which is a fundamentally different and potentially safer approach^{[1][2][3][4][5][7][8][9]}.

Comparison: PT-10 / Thymalin vs. Conventional Immunostimulants vs. Other Khavinson Bioregulators

Clinical Evidence, Russian Long-Term Mortality Data, and Current Status

The clinical evidence base for PT-10 and its predecessor Thymalin is among the most extensive of all Khavinson peptide bioregulators, though it is primarily from Russian research and has not been replicated in large-scale Western peer-reviewed clinical trials. The evidence includes the following key studies and findings^{[1][2][3][4][5][6][9][10]}:

Historical development and regulatory approval (1970s-1982): Thymalin was developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in Leningrad, as part of Soviet military medical research aimed at developing treatments for radiation-induced immunodeficiency (a concern during the Cold War, given the potential for nuclear conflict and radiation exposure). The compound was extracted from the thymus glands of young calves and was found to have immunomodulatory properties in preclinical studies. On November 10, 1982, Thymalin was approved for medical application as an immunomodulator by USSR Ministry of Health Order No. 1008 (Registration No. 82.1008.8), making it one of the first peptide bioregulators to receive regulatory approval. It remains in clinical use in Russia today, manufactured by Samson-Med, and is used for various conditions associated with immune dysfunction, including viral and bacterial infections, immunodepression, depression of hematogenesis after chemical and radiotherapy, and regeneration normalization. In experimental studies, Thymalin was also proven capable of promoting a significant decrease in neoplasm (tumor) incidence both in intact animals and after exposure to ionizing radiation or carcinogens — an intriguing finding that suggests potential anti-carcinogenic effects, though this has not been confirmed in human clinical trials^{[1][2][3][6][10]}.

25-year long-term study (n=800, Saint Petersburg): One of the most remarkable studies in the Khavinson research program is a 25-year long-term study involving approximately 800 patients in Saint Petersburg, which evaluated the effects of Thymalin (and related peptide bioregulators) on mortality and infectious disease incidence in elderly populations. According to the published results, long-term Thymalin treatment was associated with a 28% reduction in mortality and a 40% reduction in infectious disease incidence compared to control groups. These are striking findings — a 28% mortality reduction over 25 years is a very large effect size, comparable to or exceeding the effects of many established interventions (such as statin therapy for cardiovascular disease prevention, which typically reduces mortality by 15-30% in high-risk populations). However, it is important to note that these results are from a single-national (Russian) study program, the detailed methodology and peer-reviewed publication record may be limited in the Western literature, and the results have not been independently replicated in large-scale Western randomized controlled trials. Nevertheless, the magnitude of the reported effect, combined with the long duration of follow-up (25 years) and large sample size (800 patients), makes this study a cornerstone of the evidence base for Thymalin and thymic peptide bioregulation^[1][4][5][9].

6-year cohort study (n=266, age 60+): Another key study is a 6-year cohort study involving 266 elderly subjects (age 60+), which evaluated the effects of annual Thymalin courses (10 mg per day for 5-6 consecutive days, administered annually) on all-cause mortality. According to the published results, annual Thymalin treatment was associated with a ~2-fold (2.0-2.1×) reduction in all-cause mortality compared to untreated controls. This means that subjects receiving annual Thymalin courses had approximately half the mortality rate of control subjects over the 6-year study period — again, a very large effect size. The study also found that when Thymalin was combined with Epithalon (the pineal tetrapeptide AEDG, another Khavinson bioregulator with telomerase-activating and circadian-regulating effects), the mortality reduction reached 4.1-fold with repeat annual dosing — meaning that subjects receiving the combination of both peptides had approximately one-quarter the mortality rate of control subjects. This synergistic effect is consistent with the hypothesis that different Khavinson bioregulators target different tissues and biological pathways (Thymalin = immune system/thymus, Epithalon = pineal gland/aging clock/telomeres), and that combining them can produce additive or synergistic benefits across multiple organ systems. However, as with the 25-year study, these results are from the Russian research program and have not been independently replicated in Western clinical trials^{[4][5][9][10]}.

Randomized controlled trial (n=120, age 65-89, 12 months): A randomized controlled trial (RCT) involving 120 elderly subjects (ages 65-89) compared Thymalin treatment to placebo over a 12-month period. The results showed that Thymalin-treated subjects had a 67% increase in T-cell proliferation response compared to baseline and controls — indicating significant improvement in T-cell function, which is a key marker of immune competence that typically declines with aging (immunosenescence). This RCT provides more rigorous evidence (randomized, placebo-controlled design) for the immune-enhancing effects of Thymalin, though it was still conducted within the Russian research program and the sample size (120 subjects) is relatively modest. The 67% increase in T-cell proliferation is a clinically meaningful improvement — T-cell proliferation capacity is critical for mounting effective immune responses against pathogens and cancer cells, and its decline with age is a major contributor to the increased susceptibility of older individuals to infections and cancer^[4][5][9].

Preclinical and mechanistic studies: In addition to clinical studies, there is an extensive body of preclinical research on Thymalin and its constituent short peptides (EW, KE, EDP), including: (a) in vitro molecular studies demonstrating that the short peptides EW, KE, and EDP can complementarily bind to specific DNA sequences and histone proteins, leading to changes in gene expression and synthesis of heat-shock proteins and cytokines; (b) in vitro immune cell studies showing that Thymalin promotes T-cell precursor maturation, normalizes differentiation and proliferation, reduces apoptosis of lymphoid cells, activates cellular immunity reactions, and normalizes immune cell ratios; (c) animal studies demonstrating reversal of age-related thymic involution markers (increased TREC counts, improved naive T-cell ratios), reduced tumor incidence (both in intact animals and after radiation/carcinogen exposure), and improved immune responses to infection; and (d) structure-activity relationship studies comparing the EW, KE, and EDP peptides and their contributions to the overall biological activity of Thymalin. These preclinical studies provide mechanistic support for the clinical findings and help explain how thymic short peptides produce their immune-restorative effects at the molecular and cellular level^{[1][2][3][7][8][10]}.

Current status and important caveats: Despite the extensive Russian clinical data, it is critical to contextualize the evidence base for PT-10 and Thymalin: (1) NOT FDA-approved — Thymalin is approved as an immunomodulator in Russia (since 1982), but PT-10 and its constituent synthetic short peptides (EW/Thymogen, KE/Vilon, EDP) are NOT FDA-approved for any indication in the United States, and are not approved as prescription medications in most Western countries; they are classified as research chemicals/investigational peptides; (2) single-national evidence base — the vast majority of clinical data is from the Russian research program (Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology), with limited independent replication in peer-reviewed Western clinical trials; while Russian clinical research can be rigorous, the lack of Western replication is a significant limitation; (3) no clear single receptor or molecular target — unlike conventional drugs with well-characterized receptor targets, the proposed mechanism of action (complementary DNA/histone binding, chromatin decondensation, gene reactivation) remains a working hypothesis that has not been fully confirmed by high-resolution structural biology techniques (X-ray crystallography of peptide-DNA complexes, ChIP-seq genome-wide binding studies, etc.) in mainstream molecular biology; (4) no clinically established dose for synthetic PT-10/Thymogen — while Thymalin has established dosing in Russian clinical use (typically 10 mg/day for 5-10 days as a course, repeated annually or as needed), the optimal dosing for the synthetic short peptide formulations (PT-10, Thymogen/EW) has not been established through formal Phase I/II dose-finding clinical trials, and vendor-recommended dosing is based on extrapolation from Thymalin data and general Khavinson peptide dosing patterns; (5) product quality variability — as research chemicals sold by numerous online vendors, the quality, purity, potency, and accuracy of labeling of PT-10 and related peptides can vary dramatically between vendors, with potential for under-dosing, contamination, mislabeling, or counterfeit products; (6) unknown long-term safety in Western populations — while Thymalin has a long history of clinical use in Russia with generally good tolerability, the long-term safety of synthetic PT-10/Thymogen in Western populations has not been established, and theoretical concerns include potential immune overactivation (though lower risk as an immunomodulator vs. stimulant), potential effects on cancer risk (gene reactivation in cells with pre-existing oncogenic mutations — a theoretical concern that has NOT been demonstrated, and preclinical data actually suggests reduced tumor incidence), and potential interactions with other medications or supplements; and (7) regulatory/legal considerations — the sale of PT-10 for human consumption (as opposed to laboratory research use) may violate FDA regulations, particularly if the product is marketed for human therapeutic use or for the treatment of medical conditions; individuals should be aware of and comply with their local laws and regulations regarding research peptides. In summary, PT-10 and Thymalin represent a fascinating and potentially transformative approach to immune restoration and healthy aging — addressing the root cause of immunosenescence (thymic involution and age-related gene silencing) rather than downstream symptoms — but the evidence base, while extensive in the Russian context, requires independent Western validation before these compounds can be considered established therapies. The product offered here is injectable PT-10 (10mg vial), intended for in-vitro laboratory research use only — it is not for human or veterinary use^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Khavinson VKh, Linkova NS, Chalisova NI. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Bull Exp Biol Med. 2021;171(4):512-518. (Thymalin polypeptide drug used for immune dysfunction, infections, regeneration, immunodepression, hematogenesis depression after chemo/radiotherapy; molecular mechanism of thymalin + components EW dipeptide [thymogen], KE dipeptide, EDP tripeptide analyzed; short peptides regulate gene expression + heat-shock protein + cytokine synthesis; EW/KE/EDP complementarily bind to certain DNA sequences or histone proteins → change in gene expression; PDF from khavinson.info)
2. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Bull Exp Biol Med. 2003;136(3):264-267. (Thymalin = polypeptide complex extracted from thymus; approved for medical application as immunomodulator by USSR Ministry of Health Order No. 1008 of 10.11.1982 [Registration No. 82.1008.8]; experimental studies: significant decrease in neoplasm incidence both in intact animals and after ionizing radiation or carcinogens; peptides of pineal [epithalon] + thymus [thymalin] prolong human life; PDF from khavinson.info)
3. North Peptide Research. What Are Bioregulator Peptides? The Khavinson Approach Explained. NorthPeptide.com. 2026. (Bioregulators = ultra-short peptides [2-4 aa] developed by Vladimir Khavinson; theorized to interact with specific DNA sequences in target tissues to regulate gene expression; each bioregulator associated with specific organ/tissue; unlike most research peptides that act on cell surface receptors, bioregulators theorized to enter nucleus + bind DNA/histones)
4. Buy Peptides Online Research. Buy Khavinson Bioregulator Peptides | Complete Longevity Research Guide 2026. BuyPeptidesOnline.com. 2026. (Thymalin [thymus] = immune system restoration; most extensively studied bioregulator, derived from calf thymus tissue; Study 1: RCT in 120 elderly subjects [ages 65-89] compared Thymalin vs placebo over 12 months → Thymalin-treated: 67% increase in T-cell proliferation response; Study 2: 6-year cohort [n=266, age 60+] annual 10mg×5-day courses → ~2-fold reduction in all-cause mortality; combined with Epithalon → 4.1× mortality reduction with repeat annual dosing)
5. Biomogging Research. Thymalin — Khavinson thymic bioregulator clinical outcomes. Biomogging.com. 2026. (Khavinson 6-year cohort [n=266, age 60+]: annual 10mg×5-day courses → ~2-fold reduction in all-cause mortality; combined with Epithalon → reduction reached 4.1× with repeat annual dosing; "Administration of thymalin [10 mg/day for 6 consecutive days annually] was followed by a 2.0-2.1-fold decrease in the mortality rate in...")
6. PeptideDeck Research. Thymalin — history, development, and molecular structure. PeptideDeck.com. 2026. (Thymalin = polypeptide complex extracted from calf thymus glands, originally developed in 1970s by Vladimir Khavinson + Vyacheslav Morozov at Military Medical Academy in Saint Petersburg [Leningrad], Russia; foundational compound in peptide bioregulation; contains mixture of bioactive thymic peptides, primary synthetic equivalent identified as short peptides EW [Glu-Trp, Thymogen], KE [Lys-Glu, Vilon], EDP [Glu-Asp-Pro])
7. MedsBase Research. Thymalin (Khavinson Thymic Polypeptide Bioregulator) — mechanism of action. MedsBase.com. 2026. (Mechanism across published research: T-cell precursor maturation — promotes differentiation of CD4-CD8- thymocyte precursors through CD4+CD8+ double-positive stage → mature CD4+ or CD8+ T-cell exit populations; Thymic involution reversal — rodent + human research reports improvement in age-related thymic-involution markers [increased thymic-output TREC count, improved naive-T-cell ratio]; Cytokine modulation — published in-vitro...)
8. PeptideInitiative Research. Thymalin — molecular structure, active peptides, and key outcomes. PeptideInitiative.com. 2026. (Polypeptide complex extracted from calf thymus that activates immune function + extends lifespan; born from Soviet military research; proven in clinical trials to reduce mortality by up to 4.1 times in elderly patients + halve COVID-19 deaths; Molecular Structure: Polypeptide Complex Mixture; Compound Type: EW [Glu-Trp], KE [Lys-Glu], EDP [Glu-Asp-Pro]; Key Active Peptides; Source: Calf Thymus Tissue Extract)
9. Doza Clinic Research. Thymalin: How a Soviet Military Peptide Became an Immune Correction Tool — 40 years of history. Doza.clinic. 2026. (Thymalin = polycomplex of short peptides [2 to 8 amino acids] extracted from thymus gland of young calves; acts as bioregulator of immune system, supporting T-cell function + restoring immune response balance; How differs from conventional immunostimulants: works as MODULATOR, not STIMULATOR — doesn't just boost immunity, but restores balance of immune responses; 25-year study [800 patients, St. Petersburg]: 28% reduced mortality, 40% reduced infectious disease)
10. UAE Wellness Lab Research. Khavinson short-peptide bioregulators — Epithalon and Thymalin. UAEWellnessLab.com. 2026. (Hypothesis: each tissue produces short peptides that regulate gene expression in that tissue, production declines with age, synthetic versions can restore tissue-specific function; two most-studied: Epithalon [tetrapeptide AEDG, from pineal extract] + Thymalin [oligopeptide preparation from thymus]; Russian-language clinical trials reported geroprotective endpoints in elderly cohorts; English-language replication is sparse; compounds are research-grade in...)
11. Kalios Health Research. Thymagen Preclinical — EW dipeptide. Kalios.health. 2026. (Thymagen [more commonly Thymogen in Russian pharmaceutical registry] = synthetic dipeptide [2 amino acids] consisting of L-glutamic acid + L-tryptophan linked by amide bond [Glu-Trp; EW, one-letter code]; along with Vilon [Lys-Glu; KE], Thymagen is one of two simplest members of Khavinson bioregulator system; isolated from natural calf thymic peptide complex Thymalin by reverse-phase HPLC by Khavinson + Morozov; primary active component of Thymalin)
12. Peptigrade Research. Thymalin — evidence grade and source hierarchy. Peptigrade.io. 2026. (Thymalin — bovine thymus polypeptide complex [mixture of short immunomodulatory peptides including Glu-Trp (EW), Lys-Glu (KE), and EDP]; Evidence grade: C [Mixed]; Under Peptigrade source hierarchy, single-lab/single-national-program evidence caps efficacy grades at C regardless of reported effect size)
13. PeptideStat Research. Thymalin Peptide: Khavinson Thymic Bioregulator, Evidence and Limits. PeptideStat.com. 2026. (What is it: polypeptide complex extracted from calf thymus, "thymic peptide bioregulator"; Aliases: thymus polypeptide fraction, thymic peptide extract, Khavinson thymic bioregulator; Proposed effect: promotes T-lymphocyte differentiation + maturation, normalizes immune + cytokine balance; Defined receptor: NO clear single receptor or molecular target established; Regulatory status: registered in Russia as immunomodulator; NOT FDA-approved; research-only elsewhere)